U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H6N6O2
Molecular Weight 194.1511
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEMOZOLOMIDE

SMILES

Cn1c(=O)n2cnc(C(=O)N)c2nn1

InChI

InChIKey=BPEGJWRSRHCHSN-UHFFFAOYSA-N
InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00853 https://en.wikipedia.org/wiki/Temozolomide

Temozolomide, (TMZ) (brand names Temodar and Temodal and Temcad) is an oral chemotherapy drug. It’s used for the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme. Also used as maintenance therapy for glioblastoma multiforme. Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound 5-(3-methyltriazen 1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine. This methylation of guanine residues lead to single and double-strand DNA breaks and subsequent apoptotic cell death. It is suggested that the N7-methylguanine plays a critical role in the antitumor activity of the drug, as there is a correlation between the sensitivity of tumor cell lines to temozolomide and the activity of O6-alkylguanine alkyltransferase, which is the DNA repair protein that specifically removes alkyl groups at the O6 position of guanine. Cells lines that have lower levels of AGT are more sensitive to the cytotoxicity of temozolomide. It is also suggested that cytotoxic mechanism of temozolomide is related to the failure of the DNA MMR system to find a complementary base for methylated guanine. The DNA MMR system is involved in the formation of a number of proteins that remove methylated guanine. Evidence shows that when this repair process is targeted to the DNA strand opposite the O6-methylguanine, its inability to find the correct target leads to long-lived nicks in the DNA. The accumulation of these nicks lead to the inhibition of replication in the daughter cells, thereby blocking the cell cycle at the G2-M boundary.

CNS Activity

Curator's Comment:: TMZ (TEMOZOLOMIDE) is 100% bioavailable when taken orally and, because of its small size and lipophilic properties, it is able to cross the blood-brain barrier. Concentrations in the central nervous system are approximately 30% of plasma concentrations. Once it has entered the central nervous system, TMZ can be spontaneously converted to the active metabolite. These pharmacologic properties make it an ideal agent for treating central nervous system malignancies.

Originator

Curator's Comment:: The story of temozolomide starts in the late 1970s in Birmingham, where Professor Stevens was leading a team of researchers at Aston University.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TEMODAR

Approved Use

Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment; Refractory anaplastic astrocytoma, patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine

Launch Date

9.4201918E11
Primary
TEMODAR

Approved Use

Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment; Refractory anaplastic astrocytoma, patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine

Launch Date

9.4201918E11
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.5 μg/mL
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
23.4 μg × h/mL
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.8 h
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.87 h
200 mg/m^2 single, oral
dose: 200 mg/m^2
route of administration: oral
experiment type: single
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
1.89 h
200 mg/m^2 single, oral
dose: 200 mg/m^2
route of administration: oral
experiment type: single
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
85%
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg/m2 1 times / 4 weeks multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (grade 4, 2 patients)
Thrombocytopenia (grade 4, 1 patient)
Sources:
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 3
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 3
Sources:
DLT: Thrombocytopenia...
Other AEs: Anaemia, Neutropenia...
Dose limiting toxicities:
Thrombocytopenia (grade 4, 2 patients)
Other AEs:
Anaemia (grade 3, 1 patient)
Neutropenia (grade 3, 2 patients)
Sources:
200 mg/m2 1 times / day multiple, oral
MTD
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 6
Sources:
Other AEs: Anaemia...
Other AEs:
Anaemia (grade 4, 1 patient)
Sources:
750 mg/m2 1 times / 4 weeks multiple, oral
MTD
Dose: 750 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 750 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 3, 2 patients)
Sources:
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Other AEs: Anorexia, Dizziness...
Other AEs:
Anorexia (all grades, 27%)
Dizziness (all grades, 5%)
Fatigue (all grades, 61%)
Headache (all grades, 23%)
Weakness (all grades, 7%)
Confusion (all grades, 5%)
Convulsions (all grades, 11%)
Memory impairment (all grades, 7%)
Vision blurred (all grades, 8%)
Allergic reaction (all grades, 3%)
Abdominal pain (all grades, 5%)
Constipation (all grades, 22%)
Diarrhea (all grades, 10%)
Nausea (all grades, 49%)
Stomatitis (all grades, 9%)
Vomiting (all grades, 29%)
Radiation injury NOS (all grades, 2%)
Arthralgia (all grades, 6%)
Thrombocytopenia (all grades, 8%)
Insomnia (all grades, 4%)
Coughing (all grades, 8%)
Dyspnea (all grades, 5%)
Alopecia (all grades, 55%)
Dry skin (all grades, 5%)
Erythema (all grades, 1%)
Pruritus (all grades, 5%)
Rash (all grades, 13%)
Taste perversion (all grades, 5%)
Sources:
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (all grades, 41%)
Fatigue (all grades, 34%)
Asthenia (all grades, 13%)
Fever (all grades, 13%)
Back pain (all grades, 8%)
Edema peripheral (all grades, 11%)
Convulsions (all grades, 23%)
Hemiparesis (all grades, 18%)
Dizziness (all grades, 12%)
Coordination abnormal (all grades, 11%)
Amnesia (all grades, 10%)
Insomnia (all grades, 10%)
Paresthesia (all grades, 9%)
Somnolence (all grades, 9%)
Paresis (all grades, 8%)
Urinary incontinence (all grades, 8%)
Ataxia (all grades, 8%)
Dysphasia (all grades, 7%)
Convulsions local (all grades, 6%)
Abnormal gait (all grades, 6%)
Confusion (all grades, 5%)
Adrenal hypercorticism (all grades, 8%)
Nausea (all grades, 53%)
Vomiting (all grades, 42%)
Constipation (all grades, 33%)
Diarrhea (all grades, 16%)
Abdominal pain (all grades, 9%)
Anorexia (all grades, 9%)
Weight increase (all grades, 5%)
Myalgia (all grades, 5%)
Anxiety (all grades, 7%)
Depression (all grades, 6%)
Breast pain female (all grades, 6%)
Infection viral (all grades, 11%)
Upper respiratory tract infection (all grades, 8%)
Pharyngitis (all grades, 8%)
Sinusitis (all grades, 6%)
Coughing (all grades, 5%)
Rash (all grades, 8%)
Pruritus (all grades, 8%)
Urinary tract infection (all grades, 8%)
Micturition frequency increased (all grades, 6%)
Diplopia (all grades, 5%)
Abnormal vision (all grades, 5%)
Sources:
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Other AEs: Anorexia, Dizziness...
Other AEs:
Anorexia (all grades, 19%)
Dizziness (all grades, 4%)
Fatigue (all grades, 54%)
Headache (all grades, 19%)
Weakness (all grades, 3%)
Confusion (all grades, 4%)
Convulsions (all grades, 6%)
Memory impairment (all grades, 3%)
Vision blurred (all grades, 9%)
Allergic reaction (all grades, 5%)
Abdominal pain (all grades, 2%)
Constipation (all grades, 18%)
Diarrhea (all grades, 6%)
Nausea (all grades, 36%)
Stomatitis (all grades, 7%)
Vomiting (all grades, 20%)
Radiation injury NOS (all grades, 7%)
Arthralgia (all grades, 2%)
Thrombocytopenia (all grades, 4%)
Insomnia (all grades, 5%)
Coughing (all grades, 5%)
Dyspnea (all grades, 4%)
Alopecia (all grades, 69%)
Dry skin (all grades, 2%)
Erythema (all grades, 5%)
Pruritus (all grades, 4%)
Rash (all grades, 19%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Thrombocytopenia grade 4, 1 patient
1000 mg/m2 1 times / 4 weeks multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Neutropenia grade 4, 2 patients
1000 mg/m2 1 times / 4 weeks multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Anaemia grade 3, 1 patient
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 3
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 3
Sources:
Neutropenia grade 3, 2 patients
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 3
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 3
Sources:
Thrombocytopenia grade 4, 2 patients
DLT
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 3
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 3
Sources:
Anaemia grade 4, 1 patient
200 mg/m2 1 times / day multiple, oral
MTD
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 6
Sources:
Thrombocytopenia grade 3, 2 patients
750 mg/m2 1 times / 4 weeks multiple, oral
MTD
Dose: 750 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 750 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Neutropenia grade 4, 1 patient
750 mg/m2 1 times / 4 weeks multiple, oral
MTD
Dose: 750 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 750 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Erythema all grades, 1%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Diarrhea all grades, 10%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Convulsions all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Rash all grades, 13%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Radiation injury NOS all grades, 2%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Constipation all grades, 22%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Headache all grades, 23%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Anorexia all grades, 27%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Vomiting all grades, 29%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Allergic reaction all grades, 3%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Insomnia all grades, 4%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Nausea all grades, 49%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Abdominal pain all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Confusion all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Dizziness all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Dry skin all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Dyspnea all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Pruritus all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Taste perversion all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Alopecia all grades, 55%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Arthralgia all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Fatigue all grades, 61%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Memory impairment all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Weakness all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Coughing all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Thrombocytopenia all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Vision blurred all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Stomatitis all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Amnesia all grades, 10%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Insomnia all grades, 10%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Coordination abnormal all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Edema peripheral all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Infection viral all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Dizziness all grades, 12%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Asthenia all grades, 13%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Fever all grades, 13%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Diarrhea all grades, 16%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Hemiparesis all grades, 18%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Convulsions all grades, 23%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Constipation all grades, 33%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Fatigue all grades, 34%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Headache all grades, 41%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Vomiting all grades, 42%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Abnormal vision all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Confusion all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Coughing all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Diplopia all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Myalgia all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Weight increase all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Nausea all grades, 53%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Abnormal gait all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Breast pain female all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Convulsions local all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Depression all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Micturition frequency increased all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Sinusitis all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Anxiety all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Dysphasia all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Adrenal hypercorticism all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Ataxia all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Back pain all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Paresis all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Pharyngitis all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Pruritus all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Rash all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Upper respiratory tract infection all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Urinary incontinence all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Urinary tract infection all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Abdominal pain all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Anorexia all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Paresthesia all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Somnolence all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Constipation all grades, 18%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Anorexia all grades, 19%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Headache all grades, 19%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Rash all grades, 19%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Abdominal pain all grades, 2%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Arthralgia all grades, 2%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Dry skin all grades, 2%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Vomiting all grades, 20%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Memory impairment all grades, 3%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Weakness all grades, 3%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Nausea all grades, 36%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Confusion all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Dizziness all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Dyspnea all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Pruritus all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Thrombocytopenia all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Allergic reaction all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Coughing all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Erythema all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Insomnia all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Fatigue all grades, 54%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Convulsions all grades, 6%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Diarrhea all grades, 6%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Alopecia all grades, 69%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Radiation injury NOS all grades, 7%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Stomatitis all grades, 7%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Vision blurred all grades, 9%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
PubMed

PubMed

TitleDatePubMed
Future directions for temozolomide therapy.
2001 Aug
Temozolomide for treating brain metastases.
2001 Aug
Temozolomide in combination with other cytotoxic agents.
2001 Aug
New approaches for temozolomide therapy: use in newly diagnosed glioma.
2001 Aug
Chemotherapy for the treatment of oligodendroglial tumors.
2001 Aug
Temozolomide for recurrent high-grade glioma.
2001 Aug
Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
2001 Aug
Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
2001 Aug 1
Adults with newly diagnosed high-grade gliomas.
2001 Dec
Low-grade gliomas.
2001 Dec
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
2001 Dec
Temozolomide (Temodar).
2001 Jan-Feb
Controversies in the management of brain metastases: the role of chemotherapy.
2001 Jan-Mar
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
2001 Jul
Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones.
2001 Jul
Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine.
2001 Jul
Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF).
2001 Jul
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
2001 Jul
Temozolomide chemotherapy in recurrent oligodendroglioma.
2001 Jul 24
Mapping therapeutic response in a patient with malignant glioma.
2001 Jul-Aug
Metastatic melanoma.
2001 Jun
Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature.
2001 Mar
New strategy developments in brain tumor therapy.
2001 Nov
Possible efficacy of temozolomide in a patient with gliomatosis cerebri.
2001 Nov 27
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
2001 Oct
Targeting DNA mismatch repair for radiosensitization.
2001 Oct
Current and future developments in the use of temozolomide for the treatment of brain tumours.
2001 Sep
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
2001 Sep
Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study.
2002
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
2002 Apr
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
2002 Apr
Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients.
2002 Apr 8
Multifaceted resistance of gliomas to temozolomide.
2002 Aug
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
2002 Aug 10
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
2002 Feb 12
NICE verdict on Temozolomide: where next?
2002 Feb 12
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
2002 Jan 15
Temozolomide in glioblastoma multiforme of the elderly.
2002 Jan-Feb
Pharmacological strategies to increase the antitumor activity of methylating agents.
2002 Jul
Treatment of newly diagnosed glioblastoma multiforme.
2002 Jul 15
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
2002 Jun 1
Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
2002 Jun 1
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
2002 Mar 1
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
2002 Mar 1
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
2002 Mar 15
Temozolomide as second-line chemotherapy for relapsed gliomas.
2002 May
Gateways to clinical trials.
2002 May
Clinical relevance of MGMT in the treatment of cancer.
2002 May 1
First-line therapy with temozolomide induces regression of primary CNS lymphoma.
2002 May 28
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
2016 Feb 28
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Dosage of TEMODAR must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and the neutrophil and platelet counts at the time of initiating the next cycle. For TEMODAR dosage calculations based on body surface area (BSA). Is used: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg capsules and 100 mg powder for injection
4–6 week male NOD/SCID mice were implanted intracranially with 1000 chemoresistant glioma cancer stem cells (GSCs). For analysis of NEO212 efficacy, mice were implanted intracranially with 5000 USC02 or USC04 GSCs and treated subcutaneously with vehicle (45% ethanol/glycerol and 10% DMSO) or NEO212 (25 mg/kg in vehicle). Treatment was given in a cycle of 10 days on/5 days off.
Route of Administration: Other
Glioma cells (5,000 cells/well), astrocytes or EC cells (10,000 cells/well) were seeded in 96-well plates. After 24 hours NEO212 was added to the cells at different concentrations (up to 150 mkM) and incubated for 72 hours.
Name Type Language
TEMOZOLOMIDE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
TEMOZOLOMIDE [INN]
Common Name English
MK-7365
Common Name English
NSC-362856
Code English
TEMOZOLOMIDE [EMA EPAR]
Common Name English
CCRG-81045
Code English
M&B-39831
Code English
M-39831
Code English
TEMOZOLOMIDE [EP MONOGRAPH]
Common Name English
METHAZOLASTONE
Common Name English
SCH 52365
Code English
TEMOZOLOMIDE [JAN]
Common Name English
TEMOZOLOMIDE [USAN]
Common Name English
TEMOZOLOMIDE [ORANGE BOOK]
Common Name English
TEMOZOLOMIDE [WHO-DD]
Common Name English
SCH-52365
Code English
3,4-DIHYDRO-3-METHYL-4-OXOIMIDAZO(5,1-D)-AS-TETRAZINE-8-CARBOXAMIDE
Common Name English
TEMOZOLOMIDE [USP MONOGRAPH]
Common Name English
IMIDAZO(5,1-D)-1,2,3,5-TETRAZINE-8-CARBOXAMIDE, 3,4-DIHYDRO-3-METHYL-4-OXO-
Systematic Name English
TEMOZOLOMIDE [USP-RS]
Common Name English
TEMOZOLOMIDE [MART.]
Common Name English
TEMODAL
Brand Name English
TEMOZOLOMIDE [MI]
Common Name English
M&B 39831
Code English
TEMODAR
Brand Name English
TEMOZOLOMIDE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C902
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
NDF-RT N0000175558
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
WHO-ATC L01AX03
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
NDF-RT N0000000236
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 116798
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
EMA ASSESSMENT REPORTS TEMOZOLOMIDE SUN (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
EMA ASSESSMENT REPORTS TEMOZOLOMIDE TEVA (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
EMA ASSESSMENT REPORTS TEMOZOLOMIDE SANDOZ (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
EMA ASSESSMENT REPORTS TEMOZOLOMIDE HEXAL (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 193904
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
WHO-VATC QL01AX03
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
EMA ASSESSMENT REPORTS TEMOMEDAC (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 453314
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
EU-Orphan Drug EU/3/16/1733
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 497215
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
EMA ASSESSMENT REPORTS TEMODAL (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 698519
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
LIVERTOX 932
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
EMA ASSESSMENT REPORTS TEMOZOLOMIDE ACCORD (AUTHORIZED: GLIOMA, GLIOBLASTOMA
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 117198
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
Code System Code Type Description
EPA CompTox
85622-93-1
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
MESH
C047246
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
RXCUI
37776
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY RxNorm
CAS
85622-93-1
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
EVMPD
SUB10889MIG
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
ChEMBL
CHEMBL810
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
DRUG CENTRAL
2589
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
LACTMED
Temozolamide
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
FDA UNII
YF1K15M17Y
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
INN
6027
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
MERCK INDEX
M10552
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
TEMOZOLOMIDE
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
PUBCHEM
5394
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
DRUG BANK
DB00853
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
USP_CATALOG
1643543
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY USP-RS
IUPHAR
7301
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
NCI_THESAURUS
C1244
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY